Expert Review of Neurotherapeutics
October 8, 2026
Wiesław Jerzy Cubała
Introduction Generalized anxiety disorder (GAD) is a chronic, disabling condition for which currently available pharmacotherapies have delayed onset, incomplete remission rates, treatment-emergent adverse effects and substantial real-world discontinuation. DT120, formerly MM120, is an investigational orally disintegrating tablet formulation of lysergide tartrate being developed as a single-dose...
Expert Review of Neurotherapeutics
August 18, 2026
Mario Pinzi, Alessandro Cuomo, Maria Beatrice Rescalli et al.
INTRODUCTION: Acute suicidal ideation in major depressive disorder (MDD) is a psychiatric emergency requiring rapid risk assessment, containment, and treatment. Conventional monoaminergic antidepressants have delayed onset, leaving an interval during which severe depressive distress persists. Intranasal esketamine, a rapid-acting N-methyl-D-aspartate receptor antagonist, is approved for MDD...
Expert Review of Neurotherapeutics
July 1, 2026
Stephen Rush, Henry A Nasrallah
Treatment-resistant depression (TRD) represents an unmet challenge, accounting for disproportionate morbidity, disability, and healthcare burden in depression. Limitations of monoaminergic antidepressants have prompted a conceptual shift toward models emphasizing impaired neuroplasticity, synaptic dysfunction, and network dysregulation. This expert review synthesizes preclinical, translational,...
Expert Review of Neurotherapeutics
June 1, 2025
Rosalie Girard Pepin, Fatemeh Seyfzadeh, David Williamson et al.
7 citations
Disorders of consciousness (DoC) are characterized by impaired arousal and/or awareness, ranging from coma to unresponsive wakefulness syndrome, minimally conscious state, and cognitive motor dissociation. Pharmacological treatment options remain limited, complicated by the heterogeneity of etiologies, such as traumatic brain injury, stroke, and infections. The lack of rigorous clinical trials...
Expert Review of Neurotherapeutics
April 1, 2025
Stefania Chiappini, Gaia Sampogna, Antonio Ventriglio et al.
17 citations
The phenomenology of depression is characterized by a wide array of emotional, cognitive, and physical symptoms that significantly disrupt an individual's life. Societal changes, driven by technological advancements, economic pressures, environmental concerns including climate change, and shifting cultural norms, have influenced how depression manifests and is understood. These developments...
Expert Review of Neurotherapeutics
February 1, 2025
Donatella Marazziti, Francesco Weiss, Riccardo Gurrieri et al.
4 citations
After a long period of obscurantism, a possible role of psychedelics in clinical practice has progressively become a tangible perspective during the last two decades. However, the resounding enthusiasm linked to such 'psychedelic renaissance' runs the risk to unduly minimize the possible hazards associated with these compounds, while expanding their alleged benefits to improbable panacea-like...
Expert Review of Neurotherapeutics
September 1, 2024
Joseph Blanco, Pamela Quimbaya, Manuel Mena et al.
Major Depressive Disorder (MDD) is a common mental health disorder marked by sadness, hopelessness, and anhedonia. Various therapies exist, but their effectiveness is limited. Dextromethorphan hydrobromide combined with bupropion hydrochloride (Auvelity®) is a recently approved alternative for treating this condition in adults. This review summarizes the neurobiology of major depression and...
Expert Review of Neurotherapeutics
August 1, 2024
Andreas Reis, Marlon Westhoff, Hicham Quintarelli et al.
Obsessive-compulsive disorder (OCD) is a prevalent mental health issue characterized by intrusive thoughts (obsessions) and repetitive behaviors (compulsions) that can cause significant life impairment. Despite cognitive-behavioral therapy (CBT) being the most effective treatment, some individuals experience insufficient symptom reduction or relapse. This special report explores the potential...
Expert Review of Neurotherapeutics
June 1, 2023
Harry A Fagan, David S Baldwin
55 citations
Generalized Anxiety Disorder (GAD) is a common psychiatric condition, characterized by the presence of general apprehensiveness and excessive worry. Current management consists of a range of pharmacological and psychological treatments. However, many patients do not respond to first-line pharmacological treatments and novel anxiolytic drugs are being developed. In this review, the authors first...
Expert Review of Neurotherapeutics
March 1, 2023
Zamfira Parincu, Dan V. Iosifescu
Major depressive disorder (MDD) is one of the leading causes of disability worldwide. However, many patients do not achieve an adequate clinical improvement with pharmacotherapies targeting monoamine receptors, and the onset of therapeutic benefit typically lags by 4-6 weeks. There is a significant need for mechanistically novel treatments with more rapid efficacy. Combinations of...
Expert Review of Neurotherapeutics
2023
Emmanuelle A. D. Schindler, Peter S. Hendricks
5 citations
While the majority of current research and development surrounds depression, demoralization, and substance use disorders, there are numerous reports of psychedelics having beneficial effects in other branches of medicine, including for headache disorders and chronic pain. This perspective reviews conventional forms of treatment for headache and other chronic pain disorders and describes...
Expert Review of Neurotherapeutics
2022
Manaswini Pillai, Simon Erridge, Lara Bapir et al.
27 citations
The current paucity of clinical evidence limits the use of cannabis-based medicinal products (CBMPs) in post-traumatic stress disorder (PTSD). This study investigates health-related quality of life (HRQoL) changes and adverse events in patients prescribed CBMPs for PTSD. A case-series of patients from the UK Medical Cannabis Registry was analyzed. HRQoL was assessed at 1-, 3-, and 6-months...
Expert Review of Neurotherapeutics
September 21, 2020
Hartej Gill, Barjot Gill, David C J Chen-Li et al.
62 citations
Psychedelics, such as psilocybin and MDMA, offer an alternative avenue of therapy for many mental health disorders. Available evidence indicates that psychedelics may offer a single-dose, rapid effect model that have robust effects with treatment-resistant mental disorders and a unique advantage as a possible monotherapy for mental illness. Novel clinical trials that evaluate the safety,...
Expert Review of Neurotherapeutics
January 14, 2020
Rebecca Erwin Wells, Elizabeth K. Seng, Robert R Edwards et al.
74 citations
Introduction: Migraine is the second leading cause of disability worldwide, yet many patients are unable to tolerate, benefit from, or afford pharmacological treatment options. Non-pharmacological migraine therapies exist, especially to reduce opioid use, which represents a significant unmet need. Mindfulness-based interventions (MBI) have potential as a non-pharmacological treatment for...
Expert Review of Neurotherapeutics
December 4, 2018
Kai Zhang, Kenji Hashimoto
133 citations
Introduction: Depression is one of the most disabling diseases worldwide. Approximately one-third of depressed patients are treatment-resistant to the currently available antidepressants and there is a significant therapeutic time lag of weeks to months. There is a clear unmet need for rapid-acting and more efficacious treatments. (R,S)-ketamine, an old anesthetic drug, appears now to be going...
Expert Review of Neurotherapeutics
January 16, 2017
Ricardo Pablo Garay, Carlos A. Zarate, Thomas Charpeaud et al.
79 citations
INTRODUCTION: The authors describe the medications for treatment-resistant depression (TRD) in phase II/III of clinical development in the EU and USA and provide an opinion on how current treatment can be improved in the near future. Areas covered: Sixty-two trials were identified in US and EU clinical trial registries that included six investigational compounds in recent phase III development...
Expert Review of Neurotherapeutics
August 10, 2016
Bas T.h. de Veen, Arnt Schellekens, Michel M. M. Verheij et al.
102 citations
Evidence based treatment for Substance use disorders (SUD) includes psychotherapy and pharmacotherapy. However, these are only partially effective. Hallucinogens, such as psilocybin, may represent potential new treatment options for SUD. This review provides a summary of (human) studies on the putative therapeutic effects of psilocybin, and discusses the receptor systems, brain regions and...
Expert Review of Neurotherapeutics
January 2011
Kenji Hashimoto
Some patients with major depressive disorder remain resistant to antidepressant medication. A randomized, placebo-controlled, double-blind trial demonstrated that a single subanesthetic dose (0.5 mg/kg) of the N-methyl-D-aspartate receptor antagonist ketamine caused a rapid antidepressant effect within hours in treatment-resistant patients with major depressive disorder. However, the precise...
Expert Review of Neurotherapeutics
December 2007
Marco Onofrj, Astrid Thomas, Laura Bonanni
The authors review current literature on hallucinations in Parkinson's disease (PD). Recent neuropathological studies showed that hallucinations occur in synucleinopathies and are a significant predictor of Lewy Body depositions. Therefore, hallucinations are a hallmark of PD and of dementia with Lewy Bodies. Visual hallucinations are mostly complex and kinematic; preserved or disturbed insight...